lusutrombopag   Click here for help

GtoPdb Ligand ID: 10032

Synonyms: Mulpleta® | S-888711 | S888711
Approved drug
lusutrombopag is an approved drug (Japan (2015), FDA (2018), EMA (2019))
Compound class: Synthetic organic
Comment: Lusutrombopag is an orally bioavailable, nonpeptidyl, small molecule thrombopoietin (TPO) receptor agonist [4] that was developed by Shionogi in Japan. It was the second TPO receptor agonist to receive FDA approval in 2018 (avatrombopag was the first).
Lusutrombopag demonstrates antibacterial activity in vitro with potential to be repurposed as a treatment for infections caused by drug-resistant Enterococcus spp. [3].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 14
Topological polar surface area 125.99
Molecular weight 590.14
XLogP 7.78
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCCCCOC(c1cccc(c1OC)c1csc(n1)NC(=O)c1cc(Cl)c(c(c1)Cl)C=C(C(=O)O)C)C
Isomeric SMILES CCCCCCO[C@H](c1cccc(c1OC)c1csc(n1)NC(=O)c1cc(Cl)c(c(c1)Cl)/C=C(/C(=O)O)\C)C
InChI InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1
InChI Key NOZIJMHMKORZBA-KJCUYJGMSA-N
Bioactivity Comments
Lusutrombopag is selective for the human TPO receptor, and does not activate the mouse TPO receptor [4]. It promotes proliferation of Ba/F3-hMpl cells with an EC50 of 84 nM via activation of the same signal transduction pathways as native human TPO. Incubation of HuBM-CD34-positive cells with lusutrombopag for 12 days in vitro promotes megakaryocytic colony formation, which is indicative of enhanced platelet formation.
Lusutrombopag has in vitro antibacterial activity against vancomycin-resistant strains of Enterococcus faecium and Enterococcus faecalis (MIC of 2-4 μg/ml) and demonstrates a synergistic effect in combination with aminoglycoside antibacterial drugs [3].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Thrombopoietin receptor Primary target of this compound Hs Agonist Agonist - - - 4
⤷ [4]